Scientists deliberately infect volunteers with whooping cough to study natural defenses

NCT ID NCT05847322

Recruiting now Knowledge-focused Sponsor: University of Southampton Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will intentionally expose 72 healthy adults to the bacteria that cause whooping cough to see how the body fights it off without immediate antibiotics. Participants will be monitored closely for up to 6 weeks before receiving antibiotics to clear the infection. The goal is to learn about natural immunity, how long the bacteria survive, and whether it spreads to close contacts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bordetella pertussis bacteria (whooping cough germ) and azithromycin antibiotic
What this could lead to: If successful, this study could help researchers develop better vaccines or treatments for whooping cough by understanding how the body clears the infection naturally.
What could go wrong: This is an early-stage human infection study with only 72 healthy volunteers. The infection may cause symptoms, and delaying antibiotics carries risks. Results may not apply to vulnerable populations like infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER STUDY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER STUDY

Contacts and locations

Locations

NIHR Clinical Research Facility
RECRUITING

Southampton, Hampshire, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.